RenovoRx (RNXT) Total Non-Current Liabilities (2020)
RenovoRx's (RNXT) quarterly Total Non-Current Liabilities came in at $3.3 million in Q4 2020.
Powered by 
Analysis
RenovoRx (RNXT) Total Non-Current Liabilities (2020) Analysis & Trends
RenovoRx has disclosed Total Non-Current Liabilities across 1 years of filings, most recently posting $3.3 million for Q4 2020.
- In Q4 2020, Total Non-Current Liabilities changed N/A year-over-year to $3.3 million; the TTM figure through Dec 2020 stood at $3.3 million (changed N/A YoY), while the FY2020 annual figure was $3.3 million, changed N/A from the prior year.
- Total Non-Current Liabilities came in at $3.3 million for Q4 2020 at RenovoRx.
- In the past five years, Total Non-Current Liabilities ranged from a high of $3.3 million in Q4 2020 to a low of $3.3 million in Q4 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 179.79 Bn | 174.18 Bn | 7.27 Bn | - |
| 2 | Intuitive Surgical | 127.69 Bn | 122.47 Bn | 1.96 Bn | 1.92 Bn |
| 3 | Medtronic | 117.23 Bn | 108.41 Bn | 6.34 Bn | 40.46 Bn |
| 4 | Stryker | 103.55 Bn | 100.07 Bn | 4.50 Bn | 21.28 Bn |
| 5 | Boston Scientific | 63.24 Bn | 62.70 Bn | 3.85 Bn | 17.56 Bn |
| 6 | Edwards Lifesciences | 49.97 Bn | 45.72 Bn | 1.35 Bn | 2.57 Bn |
| 7 | Alcon | 32.83 Bn | 31.37 Bn | 1.68 Bn | 6.34 Bn |
| 8 | Dexcom | 32.30 Bn | 30.35 Bn | 830.00 Mn | 3.68 Bn |
| 9 | Steris | 20.73 Bn | 20.25 Bn | 684.20 Mn | 3.44 Bn |
| 10 | RenovoRx | 83.48 Mn | 83.48 Mn | 766,000.00 | - |